Patents by Inventor Ryan James LINDER

Ryan James LINDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TrkA Inhibitor
    Patent number: 11498915
    Abstract: The present invention relates to compound of the following structure for use as an inhibitor of TrkA, as well as compositions including this compound, and methods of using this compound for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: November 15, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: David A. Coates, Ryan James Linder, Laia Malet-Sanz
  • TrkA Inhibitor
    Publication number: 20210371399
    Abstract: The present invention relates to compound of the following structure for use as an inhibitor of TrkA, as well as compositions including this compound, and methods of using this compound for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
    Type: Application
    Filed: May 24, 2021
    Publication date: December 2, 2021
    Inventors: David A. Coates, Ryan James Linder, Laia Malet-Sanz
  • KRas G12C inhibitors
    Patent number: 10968214
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 6, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, David Andrew Coates, Ryan James Linder, Sheng-Bin Peng, Mohammad Sadegh Zia-Ebrahimi
  • KRAS G12C INHIBITORS
    Publication number: 20200115375
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 16, 2020
    Inventors: David Anthony BARDA, David Andrew COATES, Ryan James LINDER, Sheng-Bin PENG, Mohammad Sadegh ZIA-EBRAHIMI